‘Buying Stuff Like It’s Going Out of Fashion’: Biotech M&A on Track for Best Year Since Pre-Covid

Why It Matters

The wave of M&A will reshape pipeline composition, mitigate revenue loss from patent expirations, and signal sustained investor confidence in biotech, influencing capital allocation across the industry.

Key Takeaways

• 2026 biotech M&A $106 B in 201 deals, aiming >$250 B.
• Average deal size jumped to $527 M, up from $365 M.
• Pharma targets $1‑5 B bolt‑on deals, avoiding mega‑mergers.
• Chinese biotech rights enable “NewCo” models despite US data limits.
• XBI index rose 50 %, reopening biotech IPO window.

Pulse Analysis

The resurgence of biopharma M&A in 2026 reflects a confluence of structural pressures and favorable financing conditions. As blockbuster drugs near the end of their exclusivity periods, companies face steep revenue gaps—so‑called patent cliffs—that compel them to seek external pipelines. At the same time, equity markets have recovered from the post‑pandemic slump, offering higher valuations and cheaper capital, even as interest rates climb. PitchBook’s data shows $106 billion already deployed this year, a pace that could eclipse $250 billion, eclipsing the 2019 pre‑COVID high.

Strategically, firms are gravitating toward bolt‑on acquisitions in the $1‑5 billion band rather than pursuing sprawling $10‑20 billion mega‑mergers, which have historically struggled to deliver synergies. These mid‑size deals focus on specific drug candidates or platforms, allowing quicker integration and fewer antitrust hurdles. GSK’s $2.2 billion purchase of RAPT Therapeutics exemplifies this approach, adding a promising oncology asset without overhauling its existing portfolio. Consequently, the average deal size has risen to $527 million, reflecting a premium on high‑quality, near‑term pipeline assets.

China’s burgeoning biotech sector is becoming a secondary engine for deal flow, despite tightening U.S. rules on Chinese clinical data. Western companies are acquiring exclusive rights to Chinese‑originated molecules and establishing “NewCo” entities to shepherd them through FDA and EMA approval pathways, a model championed by venture firm Forbion. This cross‑border strategy not only diversifies source pipelines but also taps into Chinese innovation capital. Coupled with a 50 % rally in the XBI index and a reopened IPO window, investor appetite is solidifying, suggesting the M&A boom will sustain through the remainder of the year.